Inspire Medical Investors Press Class Action Over Inspire V Rollout With Lead-Plaintiff Deadline Jan. 5

The suit claims the company overstated launch readiness and demand before August disclosures on training, billing and inventory problems that preceded a steep guidance cut and stock slide.

Overview

In the pending case in the U.S. District Court for the District of Minnesota, styled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., investors allege violations of Sections 10(b) and 20(a) and Rule 10b-5.
The putative class covers purchases from August 6, 2024 through August 4, 2025, and investors have until January 5, 2026 to seek appointment as lead plaintiff under the PSLRA.
Inspire’s August 4, 2025 update cited incomplete clinician training and onboarding, delayed claims-processing software that took effect July 1, and excess inventory that dampened uptake of Inspire V.
Following the disclosure, 2025 earnings guidance was cut by more than 80% to $0.40–$0.50 per share, and the stock fell about 32% in one day, erasing roughly $1.2 billion in market value.
Multiple plaintiffs’ firms, including Wolf Haldenstein, Kirby McInerney, The Rosen Law Firm, The Schall Law Firm and Faruqi & Faruqi, are soliciting class members, and Hagens Berman reports it is investigating the claims.